N@N

E-18 Corporation: E18 Corp. Posts Corporate Profile in BARRON'S Weekly Magazine August 17th Edition

  //house-home.news-articles.net/content/2009/08/1 .. arron-s-weekly-magazine-august-17th-edition.html
  Published in House and Home on Monday, August 17th 2009 at 13:23 GMT, Last Modified on 2009-08-17 13:23:19 by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

MINNEAPOLIS, MN--(Marketwire - August 17, 2009) - E-18 Corp. (OTCBB: [ ETEN ]) today announced its corporate profile appears in BARRON'S Weekly Magazine on Monday August 17th.

The Corporate Profile will be carried in BARRON'S national circulation.

"This reflects a commitment on the part of Protectus Medical Devices to introducing the Company's revolutionary Hypodermic Safety Syringe technology to the nation at large," said Dr. John. Salstrom, President and CEO.

"Our country pays a heavy price for the cost of needlestick injuries every year, adding an additional burden to our health care industry in the billions of dollars.

"In addition to the enormous cost to our country's healthcare industry, there is the horrible human tragedy side of the needlestick injury problem, namely, that of the nurses, doctors and health care workers who contract HIV, Hepatitis, and other blood borne diseases from such needlestick injuries, some cases of which are fatal," Dr. Salstrom continued.

"The Protectus Hypodermic Safety Syringe will prevent needlestick injuries, it will save the lives of our nurses, doctors, and health care workers, and it will contribute to reducing overall health care costs to our country," Dr. Salstrom said.

"We are pleased to introduce our revolutionary technology to the market place and we invite everyone to follow the Company's progress by visiting our website at [ www.protectusmedical.com ]."

About E-18 Corp.

E-18 Corp., through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices, develops and markets innovative safety medical percutaneous devices that, collectively, have the potential to dramatically reduce needlestick injuries for medical professionals worldwide. In the nearly $5 billion global hypodermic syringe market, the Protectus Safety Syringe, the Company's lead product, is the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of "Self-Sheathing" mandated by the U.S. Federal Government. None of the manufacturers of other devices on the market can make this claim. Protectus Medical Devices has successfully patented its automatic, self-sheathing hypodermic safety syringe product, and, based on the results of full comparison clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety Syringe) has received the required 510(k) permission from the U.S. FDA to manufacture and market the device in the U.S. More information about the Company may be found at [ www.protectusmedical.com ].

Forward-Looking Statements

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of E-18 Corp. can be found in the filings of E-18 Corp. with the U.S. Securities and Exchange Commission.